Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “REGENERX BIOPHARMACEUTICALS, INC.”

12 pharma patents match "REGENERX BIOPHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 12
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 12 pharmaceutical patents matching "REGENERX BIOPHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

12 results for “REGENERX BIOPHARMACEUTICALS, INC.” · 30,257 patents in full index Clear search

  1. US 10004785

    LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized

    REGENERX BIOPHARMACEUTICALS, INC. · Granted Jun 26, 2018 · Expires Jun 21, 2038

    granted

  2. US 9821030

    LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized

    REGENERX BIOPHARMACEUTICALS, INC. · Granted Nov 21, 2017 · Expires Nov 16, 2037

    granted

  3. US 9585941

    Eye drop formulation

    REGENERX BIOPHARMACEUTICALS, INC. · Granted Mar 7, 2017 · Expires Mar 2, 2037

    granted

  4. US 9504730

    Method of achieving a thymosin beta 4 concentration in a human patient

    REGENERX BIOPHARMACEUTICALS, INC. · Granted Nov 29, 2016 · Expires Nov 24, 2036

    granted

  5. US 9056087

    Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives

    REGENERX BIOPHARMACEUTICALS, INC. · Granted Jun 16, 2015 · Expires Jun 11, 2035

    granted

  6. US 8716215

    Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease

    REGENERX BIOPHARMACEUTICALS, INC. · Granted May 6, 2014 · Expires May 1, 2034

    granted

  7. US 8426365

    Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure

    REGENERX BIOPHARMACEUTICALS, INC. · Granted Apr 23, 2013 · Expires Apr 18, 2033

    granted

  8. US 8399412

    Method of treating or preventing tissue deterioration, injury or damage due to periodontal disease or disease of oral mucosa, and/or downregulating NF-kappabeta or supressing NF-kappabeta-mediated actions

    REGENERX BIOPHARMACEUTICALS, INC. · Granted Mar 19, 2013 · Expires Mar 14, 2033

    granted

  9. US 8399609

    Treating or preventing extracellular matrix build-up

    REGENERX BIOPHARMACEUTICALS, INC. · Granted Mar 19, 2013 · Expires Mar 14, 2033

    granted

  10. US 8383576

    LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized

    REGENERX BIOPHARMACEUTICALS, INC. · Granted Feb 26, 2013 · Expires Feb 21, 2033

    granted

  11. US 8143218

    Treatment of skin, and wound repair, with thymosin beta 4

    REGENERX BIOPHARMACEUTICALS, INC. · Granted Mar 27, 2012 · Expires Mar 22, 2032

    granted

  12. US 8093214

    Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure

    REGENERX BIOPHARMACEUTICALS, INC. · Granted Jan 10, 2012 · Expires Jan 5, 2032

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.